drugset / Trial / NCT00841854

Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication

NCT00841854

RandomizedParallel-groupOpen-labelTreatment

Summary

At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment failure rates with one week first line clarithromycin based triple therapy necessitating salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact duration of bismuth based second line treatment is not determined. Therefore, the investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple regimen as a second-line therapy.

Timeline

Start
2008-06
Primary completion
2010-05
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bismuth Potassium Citrate Unknown 300 mg
Comparator Metronidazole Small molecule 500 mg
Comparator Pantoprazole Other / unclassified 40 mg
Comparator Tetracycline Unknown 500 mg